Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27807343 | 0.77 | NPBWR1 (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3636330 | 0.72 | HDAC1 (0.68) | GAARAB9AMEN1KMT2ALOXL2 | |
| SCHEMBL21660351 | 0.72 | GAA (0.53) | GAARAB9AFAAHMEN1KMT2A | |
| SCHEMBL6603633 | 0.71 | NPBWR1 (0.52) | FAAH | |
| SCHEMBL3724300 | 0.71 | RECQL (0.60) | GAARAB9AFAAHMEN1KMT2A | |
| SCHEMBL3604074 | 0.71 | TEAD1 (0.41) | MEN1KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL3604297 | 0.71 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL23316996 | 0.70 | ALDH1A1 (0.60) | GAARAB9AFAAHMEN1KMT2A | |
| SCHEMBL25411989 | 0.70 | GAA (0.48) | GAARAB9AFAAHMEN1KMT2A | |
| SCHEMBL3609951 | 0.70 | TUBB4A (0.39) | RAB9AMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298010-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-10-18 | — | — | US | disclosed |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-07-05 | — | — | US | disclosed |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-07-05 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908887-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298010-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | GAA 2195/4885RAB9A 1296/4885FAAH 4766/4885 |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | GAA 1258/4885RAB9A 1437/4885FAAH 1340/4885 |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | GAA 2270/4885RAB9A 1523/4885FAAH 4753/4885 |
| US-20180186798-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | GAA 2270/4885RAB9A 1523/4885FAAH 4753/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | GAA 1258/4885RAB9A 1437/4885FAAH 1340/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | GAA 1258/4885RAB9A 1437/4885FAAH 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.